JSUO and IBCG Collaborate on a Global Standard for TURBT Surgical Checklists – Rikiya Taoka & Mikio Sugimoto – UroToday

A New Global Alliance to Elevate Bladder Cancer Surgery

In a significant step toward standardizing and improving care for bladder cancer patients worldwide, two of the world’s leading urological oncology organizations have announced a landmark collaboration. The Japanese Society of Uro-Oncology (JSUO) and the International Bladder Cancer Group (IBCG) are joining forces to develop and promote a global standard for surgical checklists used in Transurethral Resection of Bladder Tumor (TURBT), a foundational procedure in the diagnosis and treatment of the disease. This initiative, championed by experts including Dr. Rikiya Taoka and Dr. Mikio Sugimoto of Nara Medical University, aims to mitigate procedural variability, reduce medical errors, and ultimately enhance patient outcomes on a global scale.

Bladder cancer remains a major global health challenge, with hundreds of thousands of new cases diagnosed annually. The quality of the initial TURBT procedure is arguably the single most important determinant of a patient’s long-term prognosis. However, the execution of this critical surgery varies dramatically between institutions and across continents. By creating a unified, evidence-based checklist, the JSUO and IBCG seek to establish a new gold standard, ensuring that every patient, regardless of their location, benefits from the safest and most effective surgical practices known to modern medicine. This collaboration represents a powerful fusion of Japanese surgical precision and international consensus-building, signaling a new era of quality control in uro-oncology.

The Critical Role of TURBT in Bladder Cancer Management

To fully appreciate the gravity of this collaboration, one must first understand the pivotal role of the TURBT procedure. It is far more than a simple tumor removal; it is the cornerstone upon which all subsequent treatment decisions for bladder cancer are built.

Understanding the Landscape of Bladder Cancer

Bladder cancer is the tenth most common cancer worldwide, affecting men more frequently than women. The majority of cases—approximately 75%—are diagnosed at an early stage, when the tumor is confined to the inner lining of the bladder. This is known as Non-Muscle-Invasive Bladder Cancer (NMIBC). While NMIBC has a relatively good survival rate, it is characterized by an exceptionally high rate of recurrence. A patient diagnosed with NMIBC often faces a lifetime of surveillance, follow-up procedures, and anxiety. The primary goal of initial management is to accurately diagnose the cancer, completely remove all visible tumors, and correctly stage the disease to determine its potential for progression.

What is TURBT? A Procedural Deep Dive

Transurethral Resection of Bladder Tumor is a minimally invasive surgical procedure that serves both diagnostic and therapeutic purposes. Performed under general or spinal anesthesia, a surgeon inserts a specialized instrument called a resectoscope through the urethra and into the bladder. The resectoscope is equipped with a light, a camera, and an electrified wire loop. This allows the urologist to visualize the bladder’s interior and meticulously shave away the cancerous tumor(s) from the bladder wall, piece by piece. These tissue fragments are then evacuated from the bladder and sent to a pathologist for detailed analysis.

The pathologist’s report provides two critical pieces of information: the tumor grade (how aggressive the cancer cells appear) and, most importantly, the stage (how deeply the tumor has invaded the bladder wall). The key question is whether the tumor has penetrated the detrusor muscle layer. If it is confined to the lining (NMIBC), the treatment path is vastly different and less aggressive than if it has invaded the muscle (Muscle-Invasive Bladder Cancer, or MIBC), which often requires bladder removal (cystectomy) or intensive chemoradiation.

The High Stakes of a “Perfect” TURBT

The quality of this first TURBT is paramount. An incomplete or poorly executed procedure can have dire consequences for the patient:

• Understaging: The most dangerous error. If the surgeon fails to obtain a tissue sample that includes the underlying detrusor muscle, the pathologist cannot determine if the cancer is muscle-invasive. A patient with MIBC might be misdiagnosed as having NMIBC, leading to a critical delay in receiving life-saving aggressive therapy. Studies have shown that up to 30% of initial TURBTs lack muscle in the specimen.
• Incomplete Resection: If any part of the tumor is left behind, the risk of local recurrence skyrockets. A high-quality TURBT aims to remove all visible cancerous tissue to give the patient the best possible chance of remaining disease-free.
• Increased Complications: Hasty or improper technique can lead to complications such as bladder perforation, excessive bleeding, or infection, prolonging hospital stays and recovery times.
• Flawed Treatment Decisions: All future treatment—from intravesical chemotherapy and immunotherapy (like BCG) to decisions about bladder removal—is predicated on the information gathered from the initial TURBT. An inaccurate foundation leads to a flawed treatment structure.

Because the stakes are so high, ensuring that every TURBT is performed to the highest possible standard is not just a goal; it is a clinical and ethical imperative.

The Problem of Variability: Why a Standardized Checklist is Urgently Needed

Despite the procedure’s critical importance, there is a surprising and concerning lack of standardization in how TURBT is performed globally. This variability introduces unnecessary risks and contributes to inconsistent patient outcomes.

A Patchwork of Global Practices in Urologic Surgery

A urologist in Tokyo may follow a different set of procedural steps than one in Toronto or Berlin. These differences can manifest in numerous ways:

• Pre-operative Planning: The use of advanced imaging or enhanced cystoscopy (e.g., Blue Light Cystoscopy) to better visualize tumors is not universally adopted.
• Surgical Technique: Techniques range from traditional piecemeal resection to more modern en-bloc resection, where the tumor is removed in a single piece, potentially improving staging accuracy. The adoption of these techniques is inconsistent.
• Intra-operative Documentation: The detail with which a surgeon maps the tumor locations, sizes, and numbers in the operative report can vary, impacting the quality of follow-up surveillance.
• Post-operative Care: The administration of a single, immediate dose of post-operative intravesical chemotherapy has been proven to reduce recurrence rates, yet its application remains inconsistent due to logistical challenges and lack of standardized protocols.

This “procedural drift” means that the quality of a patient’s TURBT can be subject to the individual surgeon’s training, habits, and the institutional culture in which they practice. It’s a systemic problem that cannot be solved by individual effort alone.

The Power of the Checklist: Lessons from Aviation and Modern Medicine

The concept of a simple checklist revolutionizing a complex field is not new. The aviation industry adopted mandatory pre-flight checklists decades ago, drastically reducing pilot error and making air travel one of the safest forms of transportation. The medical community took a major leap forward with the popularization of this concept by Dr. Atul Gawande in his book “The Checklist Manifesto.”

This led to the development and global implementation of the WHO Surgical Safety Checklist. Its success has been profound. Studies have demonstrated that consistent use of the checklist significantly reduces rates of major complications and mortality in a wide range of surgeries. The checklist works not because it teaches surgeons how to operate, but because it functions as a cognitive safety net. It ensures that critical, often simple, steps are not overlooked in the complex and high-pressure environment of the operating room. It standardizes communication, reinforces best practices, and empowers every member of the surgical team to speak up for safety.

Identifying the Gaps in Current TURBT Protocols

Applying the checklist philosophy to TURBT targets specific, well-documented points of failure. Key steps that are frequently performed inconsistently or missed altogether include:

• Performing a bimanual examination under anesthesia to feel for a palpable mass, which can indicate advanced disease.
• Creating a detailed bladder diagram in the operative note to guide future cystoscopies.
• Explicitly communicating to the pathologist which tissue samples come from the tumor base to aid in staging.

– Ensuring the detrusor muscle is present in the resected specimen and documenting this goal.

– A formal “time out” to confirm the plan for immediate post-operative intravesical chemotherapy.

A standardized checklist would transform these “recommended” steps into “required” actions, hardwiring quality and safety into the procedural workflow.

A Landmark Collaboration: JSUO and IBCG Join Forces

The partnership between the JSUO and the IBCG is a strategic alliance designed to tackle this global challenge head-on. It combines the strengths of two highly respected organizations to create a tool with both deep clinical credibility and broad international reach.

Introducing the Key Players: A Fusion of National Precision and Global Vision

The Japanese Society of Uro-Oncology (JSUO): The JSUO is one of Japan’s premier medical societies, renowned for its commitment to rigorous scientific research, meticulous surgical technique, and high standards of care. Japanese urology has a long-standing reputation for precision and a data-driven approach to medicine. The JSUO brings a deep well of clinical expertise and a cultural emphasis on process and quality improvement to the project.

The International Bladder Cancer Group (IBCG): The IBCG is a global consortium of leading urologists, oncologists, pathologists, and researchers dedicated to improving the understanding and treatment of bladder cancer. Its mission is to foster international collaboration, conduct practice-changing research, and develop consensus guidelines. The IBCG provides the global platform and network necessary to ensure that the checklist is not just developed, but also validated, disseminated, and adopted by the international urological community.

The Genesis of the Partnership: A Shared Mission

This collaboration stems from a mutual recognition that improving the quality of TURBT is a “low-hanging fruit” for making a substantial impact on bladder cancer outcomes. Both organizations identified the unacceptable variability in surgical quality as a key barrier to progress. By pooling their resources and expertise, they aim to create a single, authoritative checklist that can be endorsed by major urological associations worldwide, including the American Urological Association (AUA) and the European Association of Urology (EAU), thereby creating a true global standard.

The Voices Behind the Initiative: Dr. Rikiya Taoka and Dr. Mikio Sugimoto

Driving this initiative are dedicated clinicians and researchers like Dr. Rikiya Taoka and Dr. Mikio Sugimoto from the prestigious Department of Urology at Nara Medical University in Japan. Their leadership exemplifies the bridge being built between the JSUO and the IBCG. As active members in both the Japanese and international urological communities, they are perfectly positioned to shepherd this project. Their work underscores the understanding that advancements in medicine require not only technological innovation but also a fundamental commitment to standardizing best practices to ensure every patient receives optimal care.

Crafting a Global Consensus: The Rigorous Development Process

Creating a checklist that is both comprehensive and practical for use in diverse healthcare settings is a complex task. The development process, led by the JSUO-IBCG working group, is expected to be methodical and inclusive, likely involving several key phases:

1. Systematic Review: A thorough review of existing medical literature and international guidelines to compile a list of all evidence-based best practices for TURBT.
2. Expert Consultation: Engaging a global panel of TURBT experts through surveys and consensus-building methodologies like the Delphi method to debate and vote on the most critical checklist items.
3. Drafting and Refinement: Developing an initial version of the checklist organized into logical phases of care (pre-operative, intra-operative, post-operative).
4. Pilot Testing and Validation: Implementing the draft checklist in a variety of clinical settings—from academic medical centers to community hospitals across different countries—to test its usability, clarity, and impact on procedural quality.
5. Finalization and Dissemination: Releasing the finalized, validated checklist along with educational materials and a strategy for global implementation.

Anatomy of the Proposed TURBT Checklist: A Blueprint for Excellence

While the final version is still under development, the JSUO-IBCG TURBT checklist is expected to be structured around the three critical phases of the surgical journey, mirroring the successful format of the WHO checklist.

The Pre-Operative Phase: “Sign In”

(To be completed before the induction of anesthesia)

This phase focuses on ensuring that all preparatory steps have been correctly taken and that the team is aligned before the procedure begins. Key items will likely include:

• Patient Confirmation: Confirming patient identity, the surgical site, and the procedure.
• Consent Verification: Ensuring the patient has consented not only to the TURBT but also to potential immediate post-operative intravesical chemotherapy.
• Review of Findings: Verbally reviewing previous cystoscopy reports and imaging to ensure the entire team is aware of the number, location, and appearance of known tumors.
• Prophylaxis Check: Confirming that prophylactic antibiotics have been administered per institutional or international guidelines to prevent infection.

The Intra-Operative Phase: “Time Out”

(To be completed after anesthesia but before the first incision/resection)

This critical pause brings the entire surgical team together to confirm the plan and address key procedural goals. It ensures that the most important surgical objectives are top-of-mind.

• Team Introduction: All members of the surgical team introduce themselves by name and role.
• Procedural Plan Confirmation: The surgeon articulates the plan, including the order of resection if multiple tumors are present.
• Bimanual Exam Confirmation: A verbal confirmation that a bimanual examination has been performed and its findings (e.g., presence or absence of a palpable mass).
• Staging Goal Statement: A clear statement of the primary goal: “We will ensure a sample containing detrusor muscle is obtained for accurate staging.”
• Specimen Handling Plan: Discussing the plan for separating specimens (e.g., tumor tissue vs. deep base tissue) and labeling them correctly for the pathologist.

The Post-Operative Phase: “Sign Out”

(To be completed before the patient leaves the operating room)

This final check ensures a safe and complete handoff of the patient and secures the gains made during the procedure. It focuses on documentation and immediate post-operative actions.

• Procedure Documentation: Confirming the name of the procedure performed and that a detailed operative note, including a bladder diagram, will be completed.
• Specimen Confirmation: Verifying that all tissue samples are correctly labeled and sent to pathology.
• Intravesical Chemotherapy Decision: A final confirmation of whether immediate post-operative intravesical chemotherapy was administered or, if not, the reason for its omission (e.g., suspected perforation).
• Post-operative Plan: The surgeon summarizes the key post-operative orders, including catheter management and any concerns for the recovery team.

Global Implications and the Path Forward

The development of a global TURBT checklist by the JSUO and IBCG is more than an academic exercise; it is a pragmatic initiative with the potential to fundamentally reshape bladder cancer care.

Beyond the Checklist: A Cultural Shift in Urology

The ultimate goal of this project extends beyond the physical checklist itself. It aims to foster a global culture of safety, communication, and standardization within the urological community. By encouraging universal adoption, the initiative will establish a shared language and a common benchmark for what constitutes a “high-quality” TURBT. This will empower surgeons, nurses, and entire healthcare systems to measure their performance, identify areas for improvement, and hold themselves accountable to the highest international standards.

Overcoming Hurdles to Global Adoption

The path to universal adoption will not be without challenges. Potential hurdles include resistance to change from surgeons accustomed to their own routines, logistical difficulties in resource-limited settings, and the need for widespread education and training. The success of the initiative will depend on the ability of the JSUO, IBCG, and their partner organizations to champion the checklist, provide compelling evidence of its benefits, and offer practical support for its implementation. Securing endorsements from major regional urological societies will be a critical step in this process.

A New Benchmark for Bladder Cancer Care

In conclusion, the collaboration between the Japanese Society of Uro-Oncology and the International Bladder Cancer Group represents a pivotal moment in the fight against bladder cancer. By tackling the foundational issue of procedural quality in TURBT, they are addressing a root cause of inconsistent outcomes. If successful, this standardized surgical checklist will lead to more accurate staging, lower recurrence rates, fewer complications, and better-informed treatment decisions for countless patients around the world. It stands as a testament to the power of international collaboration and serves as a model for how a relentless focus on standardizing best practices can elevate the quality of cancer care for all.